$BIIB (Biogen Inc.)

$BIIB {{ '2015-07-24T13:18:26+0000' | timeago}} • Webcast

$BIIB 2Q15 Call: Expects to pay approx. $850MM in CVR payments in 2015. Anticipates CapEx of approx. $650-700MM, an increase over 2014. Expects Phase 3 for TYSABRI in SPMS in 2015. Phase 3 for SMN-Rx expected late 2016 or early 2017. Clinical results for Phase 2 of BAN2401 and E2609 expected in 2016.

$BIIB {{ '2017-07-10T12:58:24+0000' | timeago}} • Announcement

$BIIB appointed Amy Chevalier Efantis as VP of Government Affairs, effective July 17. Efantis brings more than two decades of legislative, public policy, and advocacy experience in the biopharma industry and the public sector. She will lead the company's federal and state government affairs activities from $BIIB's Washington, D.C., office.

$BIIB {{ '2017-06-28T12:10:03+0000' | timeago}} • Announcement

Pharma company $BIIB has appointed Catherine Steele as SVP of Corporate Affairs, effective July 17, 2007. Most recently, Steele served Novartis Pharmaceuticals as Global Head of Communications and Patient Relations. She began her biopharma career with Roche, where she worked more than a decade.

$BIIB {{ '2017-06-14T14:06:09+0000' | timeago}} • Announcement

$BIIB appointed Jean-Paul Kress as EVP and President, International, and Head of Global Therapeutic Operations, effective June 19, 2017. Kress will have direct responsibility for worldwide commercial operations outside the US and will also oversee the Rare and Specialty Disease Asset teams.

$BIIB {{ '2017-06-13T21:38:43+0000' | timeago}} • Announcement

$BIIB said Paul Clancy, EVP, Finance & CFO will leave the organization to join another biopharmaceutical company. Clancy will remain at the company through 2Q and assist with the transition. CAO Greg Covino will serve as the company's interim Principal Financial Officer as the company conducts a search for a new CFO.

$BIIB {{ '2017-05-15T13:05:04+0000' | timeago}} • Announcement

$BIIB closed asset purchase of Remedy Pharmaceuticals' Phase 3 candidate, Cirara. $BIIB plans to continue development and commercialization of Cirara. Remedy will share in cost of development for target indication for Cirara in LHI stroke. $BIIB will make $120MM upfront payment to Remedy and may also pay additional milestone payments and royalties.

$BIIB {{ '2017-05-15T13:02:59+0000' | timeago}} • Announcement

$BIIB closed asset purchase of Remedy Pharmaceuticals' Phase 3 candidate, Cirara (intravenous glyburide). The target indication for Cirara is large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality.

$BIIB {{ '2017-04-25T13:56:04+0000' | timeago}} • Webcast

With respect to the Europe launch of Spinraza, a drug used to treat spinal muscular atrophy, $BIIB commented that it is doing prelaunch on a country by country basis. The company is prioritizing the countries that it expect to get reimbursements earlier. $BIIB believes to get started in this summer in Germany and Scandinavia.

$BIIB {{ '2017-04-25T11:26:25+0000' | timeago}} • Announcement

$BIIB's Tysabri revenue for 1Q17 grew by 14% from last year. Outside the U.S., Tysabri revenue benefited by about $45MM due to reaching an agreement with the Price and Reimbursement Committee of the Italian National Medicines Agency (AIFA) related to Tysabri sales in prior periods.

$BIIB {{ '2017-04-25T11:24:05+0000' | timeago}} • Announcement

$BIIB posted 1Q17 net income of $747.6MM or $3.46 per share, down from $970.9MM or $4.43 per share last year. Revenue was $2.81Bil, up 3% from last year and an 8% increase excluding hemophilia revenues. Non-GAAP EPS increased to $5.20 from $4.79.

$BIIB {{ '2017-04-25T11:20:08+0000' | timeago}} • Announcement

$BIIB reported a drop in 1Q17 earnings due to the negative impact of settlement and license agreement with Forward Pharma including consideration of the U.S. Patent and Trademark Office (USPTO) ruling in favor of Biogen in the interference proceeding.

$BIIB {{ '2017-03-16T14:24:20+0000' | timeago}} • Announcement

$BIIB named Anirvan Ghosh as SVP of Research and Early Development (RED). Dr. Ghosh, who will begin his service at Biogen in April, joins from E-Scape Bio, where he served as chief scientific officer.

$PRGO {{ '2017-02-28T14:30:10+0000' | timeago}} • Announcement

$PRGO agreed to divest Tysabri royalty stream. Royalty Pharma will buy all of $PRGO's rights to receive Tysabri royalty payments from and after Jan. 1, 2017, which $PRGO has under agreement with $BIIB. Tysabri is FDA approved treatment for multiple sclerosis. $PRGO acquired Tysabri royalty stream rights through 2013 acquisition of Elan Corp. plc.

$BIIB {{ '2017-01-26T13:49:54+0000' | timeago}} • Webcast

$BIIB stated that the company ended 4Q16 with about $7.7Bil in cash and marketable securities, with about 30% of it in the US. In 2017, $BIIB expects to continue to repurchase shares as part of its $5Bil share repurchase program.

$BIIB {{ '2017-01-26T13:24:34+0000' | timeago}} • Webcast

$BIIB said it saw a moderate decline in TECFIDERA patients YoverY in 2016, while outside the US, patients grew 20% YoverY, a major driver of revenue growth for the company. Also, TYSABRI added over 4,000 net new patients globally YoverY, said the company.

$BIIB {{ '2017-01-26T13:03:07+0000' | timeago}} • Infographic

$BIIB Biogen Inc. Earnings AlphaGraphics: Q4 and FY16 Highlights

$BIIB {{ '2017-01-26T12:29:42+0000' | timeago}} • Announcement

$BIIB's product revenue in 4Q16 increased 3% YoverY to $2.5Bil, mainly driven by the 41% growth from Hemophilia products. During the quarter, the company repurchased 2.2MM shares for a total value of $651MM.

$BIIB {{ '2017-01-26T12:22:10+0000' | timeago}} • Announcement

For FY17, $BIIB expects revenue to be approx. $11.1Bil to $11.4Bil. GAAP diluted EPS is expected to be between $18.00 and $18.80, and non-GAAP diluted EPS is expected to be between $20.45 and $21.25 for 2017.

$BIIB {{ '2017-01-26T12:20:13+0000' | timeago}} • Announcement

$BIIB posted a 22% YoverY drop in its 4Q16 earnings to $649MM, or $2.99 per diluted share, hurt by the TECFIDERA litigation settlement and license charges. Excluding adjustments, the company's earnings grew 12% to $5.04 per diluted share. Revenue grew 1% to $2.8Bil.

$BIIB {{ '2017-01-17T15:05:49+0000' | timeago}} • Announcement

$BIIB said it will pay $1.25Bil in exchange for license agreement to Forward Pharma intellectual property. $BIIB will pay Forward Pharma royalties on net sales of $BIIB products for the treatment of multiple sclerosis that are covered by a Forward Pharma patent and have dimethyl fumarate (DMF) as an active pharmaceutical ingredient.

$BIIB {{ '2017-01-17T15:04:12+0000' | timeago}} • Announcement

$BIIB agreed to enter into a settlement and license agreement with Forward Pharma. The license agreement will provide $BIIB an irrevocable license to all intellectual property owned by Forward Pharma. Upon effectiveness of the settlement and license agreement, $BIIB will provide Forward Pharma a cash payment of $1.25Bil.

Recent Transcripts

SRPT (Sarepta Therapeutics, Inc.)
Wednesday, July 19 2017 - 8:30pm
ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
MCK (McKesson Corporation)
Thursday, May 18 2017 - 9:00pm
SGMO (Sangamo Biosciences Inc.)
Wednesday, May 10 2017 - 9:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
RGEN (Repligen Corporation)
Thursday, May 4 2017 - 12:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 12:30pm
QGEN (Qiagen NV)
Wednesday, May 3 2017 - 1:00pm
TECH (Bio-Techne Corp.)
Tuesday, May 2 2017 - 1:00pm
SRPT (Sarepta Therapeutics, Inc.)
Thursday, April 27 2017 - 8:30pm
VRTX (Vertex Pharmaceuticals Incorporated)
Thursday, April 27 2017 - 8:30pm
SGEN (Seattle Genetics, Inc.)
Thursday, April 27 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm
ALKS (Alkermes plc)
Thursday, April 27 2017 - 12:30pm
ACOR (Acorda Therapeutics, Inc.)
Thursday, April 27 2017 - 12:30pm

AlphaGraphics you may like